Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency of atezolizumab, carboplatin and nab-paclitaxel (Arm A) versus pembrolizumab, cis-/carboplatin and pemetrexed (Arm B) as first-line treatment.
Description for laymen
This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency of atezolizumab, carboplatin and nab-paclitaxel (Arm A) versus pembrolizumab, cis-/carboplatin and pemetrexed (Arm B) as first-line treatment.
JSON Data
{
"short_title": "ANTELOPE",
"data_mode": "900",
"data_mode_number": "000002285",
"official_title": "Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": "NCT05689671",
"eudract_number": null,
"general_contact_email": "oncostudy@ukdd.de",
"general_contact_phone": "+49 351-4587666",
"hauptpruefer_dd_name": "Dr. med. Felix Saalfeld",
"description_laie_de": "Die ANTELOPE Studie ist eine offene, randomisierte, kontrollierte, multizentrische Phase-II-Studie mit zwei Armen. Patienten mit metastasiertem TTF-1-negativem, behandlungsfreiem Lungenadenokarzinom ohne verwertbare genomische Ver\u00e4nderungen werden im Verh\u00e4ltnis 1:1 randomisiert, um die Wirksamkeit von Atezolizumab, Carboplatin und nab-Paclitaxel (Arm A) gegen\u00fcber Pembrolizumab, cis-/Carboplatin und Pemetrexed (Arm B) als Erstlinienbehandlung zu untersuchen.",
"description_laie_en": "This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency of atezolizumab, carboplatin and nab-paclitaxel (Arm A) versus pembrolizumab, cis-/carboplatin and pemetrexed (Arm B) as first-line treatment.",
"description_expert_de": "Die ANTELOPE Studie ist eine offene, randomisierte, kontrollierte, multizentrische Phase-II-Studie mit zwei Armen. Patienten mit metastasiertem TTF-1-negativem, behandlungsfreiem Lungenadenokarzinom ohne verwertbare genomische Ver\u00e4nderungen werden im Verh\u00e4ltnis 1:1 randomisiert, um die Wirksamkeit von Atezolizumab, Carboplatin und nab-Paclitaxel (Arm A) gegen\u00fcber Pembrolizumab, cis-/Carboplatin und Pemetrexed (Arm B) als Erstlinienbehandlung zu untersuchen.",
"description_expert_en": "This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency of atezolizumab, carboplatin and nab-paclitaxel (Arm A) versus pembrolizumab, cis-/carboplatin and pemetrexed (Arm B) as first-line treatment.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 10,
"sub_cat_id": 50
}
